Our Research

SRUK fund vital, innovative research into the causes, progression, and treatment of both Scleroderma and Raynaud’s. We have invested over £12 million since the formation of SRUK’s two founding charities. 

SRUK are the only UK charity funding medical research into Raynaud’s and Scleroderma. The research we support results in vital discoveries of new treatments and therapies, and helps to evolve of our understanding of the causation and progression of both conditions. Since SRUK’s formation in 2016 we have invested over £2 million in research aligning to the 4 priority areas identified by our community and clinical experts; precision medicine, early detection and diagnosis, quality of life, and causes, as established in our research strategy.  

To find out more about the pioneering research projects that your money is helping to support, visit the pages below. 

The Raynaud’s and Scleroderma Association (RSA) and the Scleroderma Society (SS) merged in 2016 to become SRUK, having being founded separately in 1982. Both had a rich history of providing excellent support services to the community and investing in research to improve the knowledge and understanding of these conditions. Between them, they funded over £10 million in research – leading to many breakthroughs which are highlighted in our Impact Report.

SRUK’s research policy is guided by both our Research Strategy, and the Association of Medical Research Charities (AMRC) of which we are a proud member.  

Untitled design (3).jpg

Our statement on the use of animals in research.